14.00
+11.11%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Launxp Biomedical Co
Its shares trade on Taipei Exchange under the ticker 6876.TWO. It has been listed since 18 January 2024. In the fiscal year to 31 December 2024, it reported revenue of TWD 2.5m and a net loss of TWD 82.6m. At that date it held total assets of TWD 123.9m and shareholders' equity of TWD 108.9m.
Launxp Biomedical Co Ltd is a TW-based company operating in industry. The company is headquartered in Taichung, Taichung. The company went IPO on 2024-01-18. Launxp Biomedical Co Ltd is a Taiwan-based company mainly engaged in the development of new drugs. The firm mainly develops cancer drugs. The main products include LXPA1788, LXPA1988, LXPA5948, LXPB5268, LXPB5101, LXPB8101, LXPB9568, LXPB977 and others. LXPA1788 is a new ingredient and new drug, a multi-target kinase inhibitor. LXPA1988 is a new ingredient and new drug with a novel chemical structure. The company exhibits high inhibitory activity against the fms-like tyrosine kinase 3 (FLT3) kinase and its mutations, inhibiting FLT3 signaling in acute myeloid leukemia (AML) cancer cells and thereby inhibiting tumor growth. LXPA5948 is a new ingredient and new drug. LXPB5268 is a new drug for new indications. LXPB5101, LXPB8101, LXPB9568, and LXPB977 are new drugs with new indications and new dosage forms.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- N/A
- Industry
- N/A
- Listed since
- 18 Jan 2024
- Website
- launxp.com ↗
Leadership
Pay as last reported
- Qiuhong ChenGeneral Manager, since 2025
- Shifeng YanDeputy General Manager, Head of Finance
- Rende YangDirector
- Jiaru LinIndependent Director
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Launxp Biomedical Co Ltd develops innovative cancer drugs like LXPA1788 and LXPA1988 with multi-target kinase inhibitors.
- The company focuses on new drug development for cancer treatment with products such as LXPA5948 and LXPB5268.
- LXPA1988 shows high inhibitory activity against FLT3 kinase mutations in acute myeloid leukemia cancer cells.
Weaknesses
- The company has only one IPO listing date of 18 January 2024 with no prior market presence.
- Launxp Biomedical Co Ltd operates solely in Taiwan with no international expansion mentioned.
- The company's product portfolio includes only new drugs without established market share.
Opportunities
- The growing cancer drug market in Taiwan offers opportunities for Launxp Biomedical Co Ltd to expand its product range.
- New drug development for cancer treatment in the Health Care industry presents opportunities for Launxp Biomedical.
- The company can leverage new indications for LXPB5101 and LXPB8101 to enter new market segments.
Threats
- The company faces competition from established pharmaceutical firms in the Taiwan cancer drug market.
- Regulatory challenges in the Health Care industry could delay new drug approvals for Launxp Biomedical.
- The lack of international presence may limit market access for Launxp Biomedical Co Ltd in global cancer drug markets.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.